Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines

Nancy L. Price, Guillaume Goyette-Desjardins, Harald Nothaft, Ezequiel Valguarnera, Christine M. Szymanski, Mariela Segura, Mario F. Feldman

Research output: Contribution to journalArticlepeer-review

90 Scopus citations


The World Health Organization has indicated that we are entering into a post-antibiotic era in which infections that were routinely and successfully treated with antibiotics can now be lethal due to the global dissemination of multidrug resistant strains. Conjugate vaccines are an effective way to create a long-lasting immune response against bacteria. However, these vaccines present many drawbacks such as slow development, high price, and batch-to-batch inconsistencies. Alternate approaches for vaccine development are urgently needed. Here we present a new vaccine consisting of glycoengineered outer membrane vesicles (geOMVs). This platform exploits the fact that the initial steps in the biosynthesis of most bacterial glycans are similar. Therefore, it is possible to easily engineer non-pathogenic Escherichia coli lab strains to produce geOMVs displaying the glycan of the pathogen of interest. In this work we demonstrate the versatility of this platform by showing the efficacy of geOMVs as vaccines against Streptococcus pneumoniae in mice, and against Campylobacter jejuni in chicken. This cost-effective platform could be employed to generate vaccines to prevent infections caused by a wide variety of microbial agents in human and animals.

Original languageEnglish
Article number24931
JournalScientific reports
StatePublished - Apr 22 2016


Dive into the research topics of 'Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines'. Together they form a unique fingerprint.

Cite this